ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
eBIMIC: development of a web platform for real-time access to cumulative antimicrobial susceptibility reports and its potential impact on evidence-based antibiotic prescribing in bacteremia.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTimely knowledge of local epidemiology is essential for guiding appropriate antibiotic therapy in severe infections such as bloodstream infections (BSI). In 2024, we developed "eBIMIC", a web-based application that enables real-time parameterized consultation of cumulative antimicrobial susceptibility data base on demographic and microbiological parameters. Avaliable to all clinicians within the Clínico-Malvarrosa Health Department (Valencia, Spain). This study evaluated its potential impact on optimizing antibiotic therapy in BSI patients admitted from the Emergency Department (ED).
methodsWe retrospectively analyzed 212 adult patients with positive blood cultures from the ED between January and December 2023. Empirical and semi-targeted treatments were compared with eBIMIC-based susceptibility data using patient sex, age, ED location, and Gram stain results (for empirical therapy), or species identification (for semi-targeted therapy). A susceptibility rate ≥ 85% was considered optimal. Potential for antibiotic de-escalation was also evaluated.
resultsEmpirical therapy was adequate in 85% of cases, and eBIMIC correctly predicted optimal coverage in 74.4% of them. Among inadequate treatments, eBIMIC successfully identified 78.1% as suboptimal. Concordance with semi-targeted therapy was high (92.6%). eBIMIC also revealed opportunities for safe de-escalation in 86% of patients receiving high-impact antibiotics. Retrospective simulation confirmed that eBIMIC would have recommended at least one effective empirical option in 99.5% of cases and matched in vitro susceptibility patterns in 92.9% of semi-targeted therapies.
conclusioneBIMIC is a mobile-accessible platform that integrates real-time microbiological data with demographic parameters to support individualized antibiotic selection and de-escalation. Its implementation has the potential to enhance antimicrobial stewardship by promoting timely, evidence-based therapeutic decisions in routine clinical settings.
Indexed as
Identifiers
41557113What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.